Gibson Dunn Guides Mentari Therapeutics in Merger with InMed Pharmaceuticals and $290 Million Private Placement
Gibson Dunn is advising Mentari Therapeutics on its merger with InMed Pharmaceuticals and a $290 million private placement. This strategic transaction aims to strengthen Mentari’s market position and operational capabilities. The legal team includes partners Ryan Murr and Branden Berns, along with associate Evan Shepherd.